From: Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study
Type of Cost | Mean | Source |
---|---|---|
Pre-Diagnosis | Â | Â |
   Number of medical visits | 1.94 | ZCQ†|
Lab costs (3 AFB smears) | $8.49 | [92] |
Patient out-of-pocket expenditures for visits | $10.63 | ZCQ†|
   Indirect Lost income for patient/family for visits* | $1.47 | ZCQ†|
Post-Diagnosis | Â | Â |
   Hospitalisation Number of hospital days | 7.13 | ZCQ†|
   Direct Health system costs for hospital days | $98.68 | HCQ‡ |
Patient out-of-pocket expenditures: hospital days | $128.91 | ZCQ†|
   Indirect Lost income for patient/family for hospital days* | $15.61 | ZCQ†|
Direct Observation of Treatment (DOT) | Â | Â |
   Number of visits | 108 | ZCQ†|
   Direct Health system costs for visits | $78.84 | HCQ‡ |
Drug costs (new case) | $5.37 | [33] |
Patient out-of-pocket expenditures for visits | $15.12 | ZCQ†|
   Indirect Lost income for patient/family for visits* | $51.84 | ZCQ†|
Follow-up | Â | Â |
   Number of visits | 7 | ZCQ†|
   Direct Health system costs for visits | $27.44 | HCQ‡ |
Patient out-of-pocket expenditures for visits | $0.84 | ZCQ†|
   Indirect Lost income for patient/family for visits* | $4.06 | ZCQ†|
Disability Costs | Â | Â |
   Direct Patient miscellaneous direct costs** | $2.12 | ZCQ†|
   Indirect Lost income due to patient disability¶ | $138.10 | ZCQ†, HCQ‡ |
Family miscellaneous indirect costs¶¶ | $46.44 | HCQ†|
Total Cost per TB patient managed | Â | Â |
   Direct Health system | $226.43 |  |
Patient out-of-pocket and miscellaneous costs | $157.62 | Â |
   Indirect Patient/family lost income and miscellaneous costs | $257.52 |  |
   Total Health system and patient/family | $641.57 |  |
Vaccination | Â | Â |
   Initial investment§ - BCG replacement only | $1.20/vaccinated | |
   With booster (total) | $1.65/vaccinated | |
   Unit cost§§ - BCG | $2.00 | [93] |
BCG replacement only | $1.10 ††| [9] |
With Booster (total) | $3.40 | [9] |